Gli altri portali
Notizie
Comunicati Stampa
Social News
Offerte di Lavoro
Comunicati Stampa
Sezioni
Toggle navigation
Prima pagina
Elenco
Nuovo account
Inserimento
Pannello di controllo
Modifica password
Salute e Benessere
Seleziona Categoria
Tutte le Categorie
Agricoltura
Ambiente
Arte e Cultura
Cibi e Bevande
Economia
Editoria e Media
Elettronica
Energia
Fiere ed Eventi
Industria
Information Technology
Internet
Istruzione e Formazione
Moda
Non Profit
Politica e Istituzioni
Salute e Benessere
Scienza e Tecnologia
Servizi
Società
Spettacolo
Sport
Telecomunicazioni
Trasporti
Turismo
Varie
Italiano
Inglese
Spagnolo
Promising signals of effect in Annexin's RVO-study
"The observations are interesting and indicate that ANXV may have a positive effect on the course of the disease in RVO, which is in line with our hypothesis. It is not possible to draw any firm conclusions from two patients, but it is unusual for such patients to respond to just a single anti-VEGF injection in the first six months after diagnosis. We intend to recruit and treat two more patients at the current dose and up to ten patients at a higher dose to gather more safety and…
PR Newswire
11/08/2023
Emergo by UL Accredited for Research Tax Credit Programs Promoting Innovation in…
With these accreditations, French companies can include Emergo by UL work in their claim to benefit from research and development work expenses for a 30% research tax credit through France's Ministry of Economy, Finance and Industrial and Digital Sovereignty. Work conducted at Emergo by UL's laboratories in Europe is an eligible expense for the credit. With these accreditations, French companies can include Emergo by UL work in their claim to benefit from research and development work…
PR Newswire
11/08/2023
Cosmetic Antioxidants Market worth $178 million by 2028 - Exclusive Report by…
Browse in-depth TOC on "Cosmetic Antioxidants Market" Browse in-depth TOC on "Cosmetic Antioxidants Market" 283 – Tables 77 – Figures 268 – Pages Download PDF Brochure:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=144119844 Natural source segment to account for larger share in the cosmetic antioxidants market in 2022. The growth of the natural source segment of the cosmetic antioxidants market can be attributed to the formulation and stringent...
PR Newswire
11/08/2023
Navamedic ASA: Significant growth across the business
Revenues for the second quarter of 2023 was NOK 124 million, gross margin was 40.4 per cent, and adjusted EBITDA for the quarter amounted to NOK 10.5 million compared to NOK 23.7 million in 2022. The operating result (EBIT) for the second quarter was negative NOK 4.0 million, compared to NOK 21.9 million last year. Revenues for the second quarter of 2023 wasNOK 124 million, gross margin was 40.4 per cent, and adjusted EBITDA for the quarter amounted toNOK 10.5 millioncompared toNOK 23...
PR Newswire
11/08/2023
Bioretec Ltd's Half Year Report 2023 (unaudited): Historic achievement supported…
Key events in January-June 2023 Key events in January- June 2023 This half-year report is unaudited. Full year 2022 figures are audited. Key Figures Timo Lehtonen, CEO of Bioretec Ltd: " I am thrilled to share the excellent success of Bioretec in the first half of 2023. Our relentless pursuit of excellence and dedication to innovation has propelled us to new heights. In March, we achieved a historic milestone by obtaining the US FDA market authorization for our...
PR Newswire
11/08/2023
Oxurion Receives Funding of EUR One Million under Atlas Special Opportunities…
Leuven, BELGIUM, Boston, MA, US –August 11 , 2023 – 8am CET– Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company developing next-generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, has announced the completion of Tranche 4 of funding under the Subscription Agreement with Atlas.On August 10, 2023, the Company issued 40 convertible bonds with a value of EUR one million to Atlas. Under the terms of the...
Nasdaq GlobeNewswire
11/08/2023
Information on the Total Number of Voting Rights (Denominator) following…
Regulated Information - Denominator Atlas Special Opportunities, LLChas converted 6convertible bonds in Oxurion resulting in a EUR 150 ,000capital increase. This is part of Atlas Special Opportunities, LLC's EUR 20 million Capital Commitment1 that will allow Oxurion to focus on progressing its novel and differentiated back of the eye drug candidate targeting potential market opportunities of over USD 5billion.Leuven, BELGIUM ,Boston, MA, US–...
Nasdaq GlobeNewswire
11/08/2023
Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC
Regulated InformationLeuven, BELGIUM, Boston, MA, US – August11 , 2023 – 8 .00AM CETOxurion NV (Euronext Brussels: OXUR) a biopharmaceutical company developing next generation standard of care ophthalmic therapies, with clinical stage assets in vascular retinal disorders, today announced that, pursuant to Belgian Transparency legislation 1it has received a transparency notification as follows: Oxurion received a transparency notification on August 10,...
Nasdaq GlobeNewswire
11/08/2023
Epidermolysis Bullosa Market to Surge at a CAGR of ~8% During the Study Period…
Key Takeaways from the Epidermolysis Bullosa Market Report Key Takeaways from the Epidermolysis Bullosa Market Report Discover which therapies are expected to grab the major epidermolysis bullosa market share @ Epidermolysis Bullosa Market Report Epidermolysis Bullosa Overview Epidermolysis bullosa is a rare, inherited genetic disorder that affects the skin and mucous membranes. It belongs to a group of disorders known as "blistering skin diseases." Epidermolysis bullosa is...
PR Newswire
10/08/2023
GENFIT Announces the Publication of New Data on the Clinical Performance of…
Lille (France); Cambridge (Massachusetts, United States); Zurich (Switzerland);August10 , 2023-GENFIT (Nasdaq and Euronext: GNFT), a late-stage biopharmaceutical company dedicated to improving the lives of patients with rare and severe liver diseases, today announced the publication of new data on the clinical performance of NIS2+™ in older patients, for the detection of at-risk nonalcoholic steatohepatitis (NASH) inHepatology Communications1. In...
Nasdaq GlobeNewswire
10/08/2023
MDxHealth to Present Q2 and Half Year 2023 Financial Results and Corporate…
NEWS RELEASE 10AUGUST2023 , 4PM ET / 22:00 CET MDxHealth to Present Q2 and Half Year 2023Financial Resultsand Corporate Update on August 23Company to Host Conference Call with Live Q&A, August 23 , 2023 at 4:30pm ET/ 22:30 CETIRVINE, CA, and HERSTAL, BELGIUM– August 10, 2023 – MDxHealth SA (NASDAQ/Euronext: MDXH), a commercial-stage precision diagnostics company, today...
Nasdaq GlobeNewswire
10/08/2023
The Intellectual property related to Lipid Nanoparticles in Drug Delivery has…
Lipid nanoparticles possess unique physical and chemical properties and have emerged as the principal excipient for the delivery of various types of therapeutics, including small molecules, gene therapies, proteins, peptides and DNA / RNA. With increasing research and development efforts, use of lipid nanoparticles in therapeutics has the potential to revolutionize drug delivery and address unmet medical needs. Their development can lead to more efficient and effective treatment options for…
PR Newswire
10/08/2023
BMI-2004 (A Recombinant Hyaluronidase): Advancing Subcutaneous Drug Delivery -…
Dr. Hojoon Choi, Executive Vice President and Chief Strategy Officer of the company will present a podium talk titled "BMI-2004: A Breakthrough in Subcutaneous Drug Delivery" on August 16th. The presentation highlights BMI-2004's potential in enhancing patient experience and treatment outcomes where Dr. Choi will share the results from Phase 1 clinical trial of BMI-2004. "BMI-2004 demonstrated a favorable safety profile with a very low incidence of injection site reactions"…
PR Newswire
10/08/2023
Cancer Immunotherapy Market size worth USD 306,241.12 Million, Globally, by 2030…
Download PDF Brochure: https://www.verifiedmarketresearch.com/download-sample?rid=24210 Download PDF Brochure: https://www.verifiedmarketresearch.com/download-sample?rid=24210 Browse in-depth TOCon" Cancer Immunotherapy Market " 202 - Pages 126 – Tables 37 – Figures Advancements in Cancer Immunotherapy: Market Drivers, Outlook, and Key Players Immunotherapy for cancer, a revolutionary approach that is revolutionising cancer treatment, is poised to transform the...
PR Newswire
10/08/2023
Cancer Biomarkers Market size worth USD 42.4 Billion, Globally, by 2030 at 14.2%…
Download PDF Brochure: https://www.verifiedmarketresearch.com/download-sample?rid=1931 Download PDF Brochure: https://www.verifiedmarketresearch.com/download-sample?rid=1931 Browse in-depth TOCon" Cancer Biomarkers Market " 202 - Pages 126 – Tables 37 – Figures Advancements in Cancer Biomarkers Research Drive Market Expansion: Key Players Abbott Laboratories, Thermo Fisher Scientific, and Roche Diagnostics at the Forefront Due to the convergence of increased...
PR Newswire
10/08/2023
Digital Dentistry Market worth $12.2 billion | MarketsandMarkets
Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=71673710 Download an Illustrative overview:https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=71673710 Browse in-depth TOC on "Digital Dentistry Market" 305 - Tables 56 - Figures 294 - Pages Digital Dentistry Market Scope: Orthodontics accounted for the largest share of the digital dentistry market. Based on the specialty areas, the digital dentistry market is...
PR Newswire
10/08/2023
HitGen Enters into DNA-Encoded Library Based Research Service Agreement with…
"We look forward to working with the research teams at Nested to generate novel starting points for their research programs to help address the unmet needs of patients with cancer. As one of HitGen's four core technology platforms, our world-leading DEL platform is an efficient 'engine' to advance drug discovery, and has enabled hit identification and lead generation for many innovative discovery programmes by our customers and partners. We look forward to delivering useful outcome for…
PR Newswire
10/08/2023
ERS Genomics & Santa Cruz Biotechnology Enter Into CRISPR/Cas9 Licensing…
ERS founder, Dr. Emmanuelle Charpentier, won the 2020 Nobel Prize for the discovery of CRISPR/Cas9. Consequently, the ERS patent portfolio is the most comprehensive collection of proprietary rights to this gene editing technology. ERS founder, Dr.Emmanuelle Charpentier, won the 2020 Nobel Prize for the discovery of CRISPR/Cas9. Consequently, the ERS patent portfolio is themost comprehensive collection of proprietary rights to this gene editing technology. Santa Cruz Biotechnology,...
PR Newswire
10/08/2023
Vaccitech Reports Second Quarter 2023 Financial Results and Recent Corporate…
“In the second quarter of 2023, Vaccitech achieved important clinical milestones for two of our lead programs in HPV and HBV, which included the final analysis for the Phase 1b/2a trial of VTP-300 presented at EASL,” said Bill Enright, Vaccitech's Chief Executive Officer. “Looking ahead, we remain steadfast in our focus on HBV and are eagerly anticipating interim data from our ongoing Phase 2 trials which we expect to announce by the end of the year. We have been able to extend our cash...
Nasdaq GlobeNewswire
10/08/2023
Immatics Initiates Phase 1/2 Clinical Trial to Evaluate PRAME TCR Bispecific…
TCER® IMA402 is the first next-generation, half-life extended TCR Bispecific targeting PRAME to enter the clinicPatient enrollment for IMA402 Phase 1/2 trial underwayThe trial will evaluate safety, tolerability, and anti-tumor activity of IMA402 in patients with recurrent and/or refractory solid tumorsFirst clinical data expected in 2024 Tuebingen, Germany and Houston, Texas , August10 , 2023–Immatics N.V.(NASDAQ: IMTX, “Immatics”), a clinical-stage...
Nasdaq GlobeNewswire
10/08/2023
MoonLake Immunotherapeutics Reports Second Quarter 2023 Financial Results and…
Achieved landmark milestone with positive results from Phase 2 MIRA trial in hidradenitis suppurativa (HS), suggesting that, as early as week 12, the Nanobody ®sonelokimab, relative to placebo, reaches the highest clinical activity among all other therapies tested in similarly stringent pivotal-like trials; top-line 24-week data readout is expected in mid-October 2023Successfully completed randomization of the target 200 patients several weeks ahead of schedule in its global...
Nasdaq GlobeNewswire
10/08/2023
Nexstim Plc agreed on a loan with Nordea to fund investments into growth
Company Announcement , Helsinki, 10August 2023 at 2PM (EEST) Nexstim Plc agreed on a loan with Nordea to fund investments into growth Nexstim Plc (NXTMH:HEX) ("Nexstim" or "Company") has agreed on a loan totalling EUR 1.5 million with Nordea Bank. The Company plans to use the loan to fund its strategic investments as well as growth and working capital needs. The loan is to be withdrawn in full during August 2023. The loan period is five years and other...
Nasdaq GlobeNewswire
10/08/2023
atai Life Sciences Reports Second Quarter 2023 Financial Results and Operational…
Advanced multiple clinical stage assets in development, including the on-going Phase 2b study of RL-007 in patients with Cognitive Impairment Associated with Schizophrenia DMX-1002 (Ibogaine) Phase 1 results enable discussions with regulatory authorities to assess progressing into proof-of-concept study in patients with Opioid Use DisorderThe Company's $227M cash position and committed term loan funding is expected to fund operations into 1H 2026 NEW YORK and BERLIN, Aug...
Nasdaq GlobeNewswire
10/08/2023
Novo Nordisk to acquire Inversago Pharma to develop new therapies for people…
Bagsværd, Denmark and Montreal, Canada, 10 August 2023– Novo Nordisk A/S and Inversago Pharma today announced that Novo Nordisk has agreed to acquire Inversago for up to 1.075 billion US dollars in cash if certain development and commercial milestones are achieved. Inversago Pharma is a private, Montreal-based developer of CB1 receptor-based therapies for the potential treatment of obesity, diabetes and complications associated with metabolic disorders. The acquisition of...
Nasdaq GlobeNewswire
10/08/2023
Altri Comunicati
